Edwards Lifesciences Stock Price To Earnings To Growth
| EWL Stock | EUR 69.55 0.68 0.97% |
Edwards Lifesciences fundamentals help investors to digest information that contributes to Edwards Lifesciences' financial success or failures. It also enables traders to predict the movement of Edwards Stock. The fundamental analysis module provides a way to measure Edwards Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Edwards Lifesciences stock.
Edwards |
Edwards Lifesciences Company Price To Earnings To Growth Analysis
Edwards Lifesciences' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Edwards Lifesciences Price To Earnings To Growth | 3.05 X |
Most of Edwards Lifesciences' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Edwards Lifesciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Edwards Lifesciences has a Price To Earnings To Growth of 3.0467 times. This is 329.11% higher than that of the Healthcare sector and 60.35% higher than that of the Medical Devices industry. The price to earnings to growth for all Germany stocks is 37.7% higher than that of the company.
Did you try this?
Run Positions Ratings Now
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Edwards Fundamentals
| Return On Equity | 0.26 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.28 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 43.48 B | |||
| Shares Outstanding | 608.31 M | |||
| Shares Owned By Insiders | 0.82 % | |||
| Shares Owned By Institutions | 86.92 % | |||
| Price To Earning | 45.19 X | |||
| Price To Book | 7.49 X | |||
| Price To Sales | 8.30 X | |||
| Revenue | 5.38 B | |||
| Gross Profit | 4.3 B | |||
| EBITDA | 1.93 B | |||
| Net Income | 1.52 B | |||
| Cash And Equivalents | 963 M | |||
| Cash Per Share | 4.62 X | |||
| Total Debt | 596.3 M | |||
| Debt To Equity | 19.30 % | |||
| Current Ratio | 3.66 X | |||
| Book Value Per Share | 9.55 X | |||
| Cash Flow From Operations | 1.22 B | |||
| Earnings Per Share | 2.35 X | |||
| Price To Earnings To Growth | 3.05 X | |||
| Target Price | 119.36 | |||
| Number Of Employees | 17.3 K | |||
| Beta | 1.0 | |||
| Market Capitalization | 47.01 B | |||
| Total Asset | 8.29 B | |||
| Z Score | 46.8 | |||
| Net Asset | 8.29 B |
About Edwards Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Edwards Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Edwards Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Edwards Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Other Information on Investing in Edwards Stock
Edwards Lifesciences financial ratios help investors to determine whether Edwards Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Edwards with respect to the benefits of owning Edwards Lifesciences security.